Galectins in the tumor endothelium: opportunities for combined cancer therapy

Author:

Thijssen Victor L. J. L.1,Poirier Françoise2,Baum Linda G.3,Griffioen Arjan W.1

Affiliation:

1. Angiogenesis Laboratory, Research Institute for Growth and Development (GROW), Department of Pathology, University Maastricht and Academic Hospital Maastricht, the Netherlands;

2. Institute Jacques Monod, Unité Mixte de Recherche, Centre National de la Recherche Scientifique (UMR CNRS) 7592, Paris, France;

3. Department of Pathology and Laboratory Medicine, University of California School of Medicine, Los Angeles, CA

Abstract

AbstractGalectins are emerging as a family of proteins that play an important role in several steps of tumorigenesis. Evidence is accumulating that galectins are expressed by the tumor endothelium, where they contribute to different steps of tumor progression such as immune escape and metastasis. Recent studies have identified an important role for galectins in tumor angiogenesis. Moreover, it has been shown that galectins in the endothelium can be targeted for therapeutic applications. This opens a window of opportunity for the development of tumor-type independent treatment strategies. This review focuses on the expression of galectins in the tumor endothelium, their contribution to tumor progression, and their application in tumor-type independent cancer therapy.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Reference102 articles.

1. Tumor angiogenesis: therapeutic implications.;Folkman;N Engl J Med,1971

2. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation.;Griffioen;Pharmacol Rev,2000

3. Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature.;Burrows;Proc Natl Acad Sci U S A,1993

4. Targeted gene-delivery strategies for angiostatic cancer treatment.;Brandwijk;Trends Mol Med,2007

5. Tumour vascular targeting.;Neri;Nat Rev Cancer,2005

Cited by 114 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3